Alessandro Russo
Alessandro Russo
Medical Oncology Unit AO Papardo & Department of Human Pathology, University of Messina
Verified email at
Cited by
Cited by
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
A Russo, T Franchina, GRR Ricciardi, A Picone, G Ferraro, M Zanghý, ...
Oncotarget 6 (29), 26814, 2015
RET fusions in solid tumors
AY Li, MG McCusker, A Russo, KA Scilla, A Gittens, K Arensmeyer, ...
Cancer treatment reviews 81, 101911, 2019
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ...
Journal for immunotherapy of cancer 8 (2), 2020
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospectiveá…
A Russo, M Russano, T Franchina, MR Migliorino, G Aprile, G Mansueto, ...
Advances in therapy 37, 1145-1155, 2020
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ...
Nature reviews Clinical oncology 19 (1), 51-69, 2022
Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated withá…
A Russo, T Franchina, GRR Ricciardi, A Battaglia, A Scimone, R Berenato, ...
Journal of cellular physiology 233 (10), 6337-6343, 2018
Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going
A Russo, T Franchina, GRR Ricciardi, V Smiroldo, M Picciotto, M Zanghi, ...
Critical reviews in oncology/hematology 117, 38-47, 2017
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
C Rolfo, AF Cardona, M Cristofanilli, L Paz-Ares, JJD Mochon, I Duran, ...
Critical Reviews in Oncology/Hematology 151, 102978, 2020
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumabá…
A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ...
Journal for immunotherapy of cancer 9 (4), 2021
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and futureá…
A Russo, T Franchina, G Ricciardi, A Battaglia, M Picciotto, V Adamo
International journal of molecular sciences 20 (6), 1431, 2019
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development andá…
S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ...
European Journal of Cancer 142, 18-28, 2021
NSCLC and HER2: between lights and shadows
GRR Ricciardi, A Russo, T Franchina, G Ferraro, M Zanghý, A Picone, ...
Journal of Thoracic Oncology 9 (12), 1750-1762, 2014
Liquid biopsy tracking of lung tumor evolutions over time
A Russo, D De Miguel Perez, M Gunasekaran, K Scilla, R Lapidus, ...
Expert review of molecular diagnostics 19 (12), 1099-1108, 2019
Targeted therapies in early stage NSCLC: hype or hope?
A Friedlaender, A Addeo, A Russo, V Gregorc, D Cortinovis, CD Rolfo
International journal of molecular sciences 21 (17), 6329, 2020
Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient
G Rossi, A Russo, M Tagliamento, A Tuzi, O Nigro, G Vallome, C Sini, ...
Cancers 12 (5), 1125, 2020
Precision prevention and cancer interception: the new challenges of liquid biopsy
MJ Serrano, MC Garrido-Navas, JJ Diaz Mochon, M Cristofanilli, ...
Cancer discovery 10 (11), 1635-1644, 2020
Radiomic detection of EGFR mutations in NSCLC
G Rossi, E Barabino, A Fedeli, G Ficarra, S Coco, A Russo, V Adamo, ...
Cancer research 81 (3), 724-731, 2021
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study
O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ...
European Journal of Cancer 134, 19-28, 2020
Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario
G Rossi, A Pezzuto, C Sini, A Tuzi, F Citarella, MG McCusker, O Nigro, ...
Critical Reviews in Oncology/Hematology 142, 26-34, 2019
New targets in lung cancer (excluding EGFR, ALK, ROS1)
A Russo, AR Lopes, MG McCusker, SG Garrigues, GR Ricciardi, ...
Current Oncology Reports 22, 1-14, 2020
The system can't perform the operation now. Try again later.
Articles 1–20